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G
hrelin is a 28–amino acid peptide initially iso-
lated from rat and human stomachs as an
endogenous ligand for the growth hormone
secretagogue receptor type 1a (GHS-R1a) (1)
using an intracellular calcium inﬂux assay on a stable cell
expressing rat GHS-R. At the time of its discovery in 1999,
ghrelin was known to increase growth hormone release
from the pituitary gland by binding to GHS-R1a, and 1 year
later, its role in food intake and body adiposity was
described (2). Since then, numerous additional effects of
ghrelin have been demonstrated, including regulating cell
proliferation and survival, apoptosis, inﬂammation, angio-
genesis, development and reproduction as well as metab-
olism. Recently, it has become of great research interest
whether ghrelin also has a role in -cell function. This
research area is particularly important given its potential
to lead to the development of novel strategies to increase
insulin secretion for the treatment of type 2 diabetes.
In humans, circulating ghrelin levels surge immediately
before meals and fall to a nadir within 1 h after food
intake, which results in a two- to threefold variation in
plasma levels. Circulating ghrelin is primarily produced in
the stomach, but smaller amounts are also produced in the
brain, heart, lung, kidney, placenta, gastrointestinal tract,
and pancreas. Within the islets of Langerhans of the
pancreas, ghrelin production has been found in -cells,
-cells, and the more recently discovered ε -cells (3).
Ghrelin peptides exist in two major forms, unacylated
ghrelin and acylated ghrelin, and only the latter binds to
GHS-R1a. Acylation is catalyzed by ghrelin O-acyltrans-
ferase (GOAT), which is, interestingly, highly expressed in
the stomach and the pancreas in humans (4). Consistent
with the multitude of effects of ghrelin, GHS-R1a is ex-
pressed in variety of tissues. Most importantly, with regard
to insulin secretion, GHS-R1a partially colocalizes with
insulin-positive -cells in human pancreatic islets (5),
suggesting that human -cell might be directly responsive
to ghrelin stimulation.
To date, the role of ghrelin in the regulation of insulin
secretion remains controversial. Perhaps because of dif-
ferences in the experimental conditions, ghrelin was found
to inhibit insulin secretion in the majority of studies but to
stimulate insulin secretion in others. For example, ghrelin
increased cytosolic free Ca
2 concentrations in rat -cells
and increased insulin secretion in isolated rat pancreatic
islets under glucose-stimulated conditions (6). Further-
more, ghrelin increased insulin secretion from the pan-
creas of both normal and diabetic rats (7,8). In contrast,
GHS-R1a blockade by speciﬁc antagonists or ghrelin inac-
tivation using an antiserum enhanced glucose-induced
insulin release and intracellular Ca
2 concentrations in
isolated rat islets (9). Further, exogenous ghrelin de-
creased insulin secretion in isolated mouse pancreata (10),
in mouse and rat isolated islets (11), and in -cell lines
(12). In humans, data regarding the effects of ghrelin on
insulin secretion are scant and inconsistent. Although
intravenous injection of ghrelin decreased plasma insulin
and increased plasma glucose concentrations in overnight-
fasted humans in some studies that raised plasma ghrelin
at least 4.5-fold (13,14), no changes in insulin and glucose
were observed in another that raised plasma ghrelin 2- to
3-fold (15).
Tong et al. (16) in a recent issue of Diabetes have,
therefore, revisited the effects of ghrelin on -cell function
in humans using a more sensitive approach. To this end,
acyl ghrelin (0.3, 0.9, or 1.5 nmol/kg/h) or saline was
infused in 12 healthy, young, nonobese subjects on four
separate occasions in a counterbalanced fashion after an
overnight fast. After reaching steady-state plasma ghrelin
levels, an intravenous glucose tolerance test was per-
formed on each occasion to determine the acute insulin
response to intravenous glucose (AIRg), the acute C-
peptide response to intravenous glucose (ACRg) as well
the glucose disappearance constant as an index of intra-
venous glucose tolerance. The authors found that ghrelin
infusion did not alter fasting insulin or glucose concentra-
tions but signiﬁcantly decreased AIRg 30–45% in a
dose-dependent manner. Similar suppressions were seen
in the C-peptide release in response to intravenous glu-
cose, indicating that the ghrelin-induced reduction in
plasma insulin levels was not due to increased hepatic
insulin clearance. In addition, ghrelin infusion at 0.3 and
1.5 nmol/kg/h signiﬁcantly decreased the glucose disap-
pearance constant by 30%. These responses to ghrelin
infusion were associated with marked and dose-dependent
increases in plasma growth hormone and cortisol concen-
trations but unaltered plasma concentrations of glucagon,
epinephrine, and norepinephrine. The authors conclude
that exogenous ghrelin reduces glucose-stimulated insulin
secretion and glucose disappearance in humans. More-
over, they put forward that endogenous ghrelin may have
a role in physiological insulin secretion and that ghrelin
antagonists could improve -cell function.
The ﬁndings by Tong et al. provide clear proof of
concept that ghrelin can reduce glucose-stimulated insulin
secretion. The experiments were logically designed, and
the data are clear. However, there are at least two reasons
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First, ghrelin infusion at 0.3, 0.9, or 1.5 nmol/kg/h raised
plasma ghrelin levels 4.5-, 15.4-, and 22.6-fold, respec-
tively, so that these levels were within the pharmacologi-
cal range even at the lowest infusion rate. Whether plasma
ghrelin levels within the physiological range inhibit glu-
cose-induced insulin secretion in humans therefore re-
mains unclear. Admittedly, it is possible that ghrelin, due
to its local synthesis and release within the islets of
Langerhans, may reach very high concentrations at the
-cell and act via autocrine and/or paracrine rather than
systemic mechanisms. The pharmacological plasma con-
centrations of ghrelin reached in the study thus do not
exclude the possibility that endogenous ghrelin sup-
presses insulin secretion in humans as noted by the
authors. Nevertheless, because circulating ghrelin is pri-
marily produced in the stomach, experiments using lower
dose ghrelin infusion would provide valuable information.
The second reason that makes the clinical relevance of
this study uncertain is that glucose tolerance has been
determined only in response to intravenous glucose ad-
ministration but not to an oral glucose load or a mixed
meal. In contrast to intravenous glucose tolerance, oral
glucose tolerance is strongly inﬂuenced by additional
mechanisms, such as gastric emptying and the effects of
incretins. For illustration, after a 100 g oral glucose load
70–90% of the increase in peripheral plasma insulin
concentrations can be accounted for by the incretin effect
(17,18), suggesting that these mechanisms may play a far
more important role in postprandial glycemia than the
effects of ghrelin. Whether ghrelin does play an apprecia-
ble physiological role in insulin secretion and glycemia
after oral glucose ingestion hence needs to be tested.
Aside from these issues, future research will also need
to determine the mechanism(s) by which ghrelin sup-
presses insulin secretion in humans particularly if ghrelin
antagonists were to be considered as a prospective novel
strategy for the improvement of -cell function. Besides
direct, potentially autocrine and/or paracrine mechanisms,
there is evidence to suggest that ghrelin may also indi-
rectly suppress insulin secretion. For example, in rats
ghrelin inhibited glucose-stimulated insulin release when
infused into the portal vein but not when infused into the
femoral vein. Hepatic vagotomy or coinfusion with atro-
pine methyl bromide into the portal vein diminished the
inhibitory effect of ghrelin on glucose-stimulated insulin
FIG. 1. Illustration of the mechanisms by which ghrelin may suppress insulin secretion in humans: a) direct inhibition by activation of the -cell
GHS-R1a where ghrelin may act via either endocrine or paracrine mechanisms; b) indirect inhibition by activation of the hepatic branch of the
afferent vagus nerve by ghrelin sensors in the portal system; increased ﬁring of the afferent ﬁbers of the vagus nerve reduces the activity of the
efferent nerve ﬁbers in the brain, leading to decreased insulin secretion; c) indirect inhibition by activation of the sympathetic nervous system
and subsequent stimulation of the -adrenergic receptors on -cells.
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effect on glucose-stimulated insulin secretion via the he-
patic portal system and the vagus nerve (19). Furthermore,
although not observed by Tong et al. (16), ghrelin has been
found to increase plasma epinephrine levels in humans
(20), suggesting that it may also inhibit insulin secretion
via a sympathetic response.
In summary, the study by Tong et al. (16) provides
evidence that ghrelin can inhibit insulin-stimulated insulin
secretion in humans beyond question. However, given the
uncertainties of its role following oral glucose ingestion
and its effects at physiological plasma concentrations,
future studies will most importantly need to address
whether ghrelin has a physiological role in insulin secre-
tion in humans.
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